Progressive
degeneration of dopaminergic neurons in the substantia
nigra is the characteristic feature of Parkinson’s disease
(PD) and the severity accelerates with aging. Therefore, improving
dopamine level or dopamine receptor signaling is a standard approach
for PD treatment. Herein, our results demonstrate that bromophenols
2,3,6-tribromo-4,5-dihydroxybenzyl alcohol (1), 2,3,6-tribromo-4,5-dihydroxybenzyl
methyl ether (2), and bis-(2,3,6-tribromo-4,5-dihydroxybenzyl)
ether (3) from red alga Symphyocladia
latiuscula are moderate-selective human monoamine
oxidase-A inhibitors and good dopamine D3/D4 receptor agonists. Bromophenol 3 showed a promising
D4R agonist effect with a low micromole 50% effective concentration
(EC50) value. All of the test ligands were docked against
a three-dimensional (3D) model of hD3R and hD4R, and the result demonstrated strong binding through interaction
with prime interacting residuesAsp110, Cys114, and His349
on hD3R and Asp115 and Cys119 on hD4R. Overall,
the results demonstrated natural bromophenols, especially 1 and 3, from Symphyocladia latiuscula as multitarget ligands for neuroprotection, especially in PD and
schizophrenia.